Structural basis for a new mechanism of inhibition of HIV-1 integrase identified by fragment screening and structure-based design
Rhodes, D.I., Peat, T.S., Vandegraaff, N., Jeevarajah, D., Le, G., Jones, E.D., Smith, J.A., Coates, J.A., Winfield, L.J., Thienthong, N., Newman, J., Lucent, D., Ryan, J.H., Savage, G.P., Francis, C.L., Deadman, J.J.(2011) Antivir Chem Chemother 21: 155-168
- PubMed: 21602613 
- DOI: https://doi.org/10.3851/IMP1716
- Primary Citation of Related Structures:  
3NF6, 3NF7, 3NF8, 3NF9, 3NFA - PubMed Abstract: 
HIV-1 integrase is a clinically validated therapeutic target for the treatment of HIV-1 infection, with one approved therapeutic currently on the market. This enzyme represents an attractive target for the development of new inhibitors to HIV-1 that are effective against the current resistance mutations.
Organizational Affiliation: 
Avexa Ltd, Richmond, Australia. drhodes@jdjbioservices.com